Bellicum Pharmaceuticals Inc

+0.01 (+0.54%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)15.54M
Current PE2.37
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.3 Million
Adjusted EPS-$0.85
See more estimates
10-Day MA$1.88
50-Day MA$2.38
200-Day MA$3.18
See more pivots

Bellicum Pharmaceuticals Inc Stock, NASDAQ:BLCM

3730 Kirby Drive, Suite 1200, Houston, Texas 77098
Phone: +1.832.384.1100
Number of Employees: 16


Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.